Skip to main content

Volume 7 Supplement 2

Basic science, rationale, background and future of abatacept


Edited by Peter E Lipsky and Ravinder N Maini

Supported by an educational grant from Bristol-Myers Squibb Company

  1. Rheumatoid arthritis (RA) is a common destructive inflammatory disease that affects 0.5–1% of the population in many countries. Even though several new treatments have been introduced for patients with RA, a c...

    Authors: Vivianne Malmström, Christina Trollmo and Lars Klareskog
    Citation: Arthritis Research & Therapy 2005 7(Suppl 2):S15
  2. Abatacept (CTLA4–Ig) is a novel fusion protein designed to modulate the T cell co-stimulatory signal mediated through the CD28–CD80/86 pathway. Clinical trials have provided preliminary evidence of the efficac...

    Authors: Eric M Ruderman and Richard M Pope
    Citation: Arthritis Research & Therapy 2005 7(Suppl 2):S21
  3. T cells, in particular CD4+ T cells, have been implicated in mediating many aspects of autoimmune inflammation. However, current evidence suggests that the role played by CD4+ T cells in the development of rheuma...

    Authors: Alla Skapenko, Jan Leipe, Peter E Lipsky and Hendrik Schulze-Koops
    Citation: Arthritis Research & Therapy 2005 7(Suppl 2):S4

Annual Journal Metrics

  • 2022 Citation Impact
    4.9 - 2-year Impact Factor
    5.7 - 5-year Impact Factor
    1.501 - SNIP (Source Normalized Impact per Paper)
    1.592 - SJR (SCImago Journal Rank)

    2023 Speed
    11 days submission to first editorial decision for all manuscripts (Median)
    111 days submission to accept (Median)

    2023 Usage 
    1,885 Altmetric mentions